

## ALAPIS HOLDING INDUSTRIAL AND COMMERCIAL SOCIETE ANONYME OF PHARMACEUTICAL AND CHEMICAL PRODUCTS

## (Company's Number in the Register of Societes Anonymes: 8057/06/B/86/11) REGISTERED ADRESS: 2, AFTOKRATOROS NIKOLAOU STR, P.C. 17671 ATHENS DATA AND INFORMATION FOR THE YEAR 1 JANUARY 2010 TO 31 DECEMBER 2010

According to L2190, article 135 for entities published financial statements in accordance with IFRS

The following data and information aim at providing general information on the financial standing and the financial results of ALAPIS SA. We, therefore, recommend the reader, before proceeding to any kind of investment or other transaction with the company, to look to the company's website, where financial statements under IFRS together with the Audit report are presented.

COMPANY DETAILS Ministry of Finance, Competition & Shipping Aristotelis Charatampakis: President, Mario Al-Jebouri: Vice President, Stillanos Kimparidis: Managing Director, Evridiki Georgakaki: Member, Nikolaos Karantanis: Member March 29th, 2011 Approval date for issuing by the Board of Directors : Certified Auditor Accountant : Vrasidas Damilakos R.N.SOEL (GR) 22791 BDO CERTIFIED & REGISTERED AUDITORS AE Audit Company : Type of Report Unqualified Opinion - emphasis of matter STATEMENT OF FINANCIAL POSITION (amounts in thousands STATEMENT OF CASH FLOWS (amounts in thousands €) The Group The Company
1.1.-31.12.2010 1.1.-31.12.2000 1.1.-31.12.2010 1.1.-31.12.200 Operating activities
Profits before taxes (continuous operatio
Profits before taxes (discontinuous opera
Plus/ less adjustments for:
Opereciation and amortization
Gain /(Loss) from disposal of tangible assets Property, plant and equipment 46.180 372.802 26.451 87.695 25.544 879.442 275.406 23.077 133.883 163.715 131.142 459 (1.065) 3.141 (2.914) (494) 45.720 139.721 1.950 (11.177) 789.537 177.049 78.166 93 (5.435) Inventories Trade receivables Other current assets Non current assets available for sale 147.629 229.551 274.983 334.680 214.889 (4.059) 840.543 visions airment of Property ,Plant, Equipment and Intangible Assets 118 6.939 44.497 change differences sults (income, expenses, gain, loss) from investing activity (100) 55.764 2.226.739 3.367.458 2.178.291 3.311.971 OTAL ASSETS rest expense 51.296 42.436 EQUITY AND LIABILITIES less changes in working capital: base / (increase) of inventories base / (increase) of trade receivables base / (increase) of other receivables Share capital
Other equity items
Total owners' equity (a)
Non controlling interests (b
Total equity (c) = (a) + (b) (2.863) 198.767) 47.603 78.391 28.259 417.205 1.005.565 1.359.809 467.439 1.055.799 1.401.538 1.989.898 1.005.534 1.948.261 1.055.799 1.989.898 ecrease) / Increase of other liabilities (excluding borrowing Long term borrowings 735.000 121.97 (51.824) 136.633 ions / other long term liabilities 819.544 242.564 812.222 173.636 ss.
erest paid
xes paid
perating cash flow from discontinued operation
et cash flows from operating activities (a) 1 221 205 1.419.197 1.122.491 1.322.07 TOTAL EQUITY AND LIABILITIES (c)+(d) 2.226.739 3.367.458 2.178.291 3.311.97 STATEMENT OF COMPREHENSIVE INCOME (amounts in (69.342) (393.456) 1.094 uisition/(Disposal) of subsidiaries, related, joint ventures and other inves chase/(Disposal) of tangible and intangible assets (299.723) (212.562) (202.192) 256 0 The Group 1.1. - 31.12.2010 1.1. - 31.12.2009 Total (4.781) (4.793) 86.871 (552.520) 1.232.462 946.580 219.305 286.194 148.967 124.004 (87.853) (62.899) 37.915 (11.131) (20.587) (24.974) Gross profit/(loss)
Profit before tax, financial and investing results (EBIT) (859.898) (922.746) (931.578) (848.766) 18.309 8.505 **2.248** (902.158) (906.604) 79.352 **50.106** ofit/(loss) (a) Financing activities sue of share capital roceeds / (Payments) from borrowings 423.063 Owners of the parent (906.411) (24.974) 2.248 3.941 16.008 (10.061) 4.006 (58.223) 23.966 16.167 (9.998) 4.006 OCCEUTS (Trayments) in in the intermined in incipal repayments of finance lease obligations vidends paid urchase) of Treasury shares/Gain from disposal of share capital's issue rights n-controlling interests (193) (193) (536)(13.920) (12.619) (11.333) 289 (931.289) (24.160) 25.946 289 (906.315) (24.974) 2.248 (1.336) 457.20 cash flows from financing activities (c) (87,731) Owners of the parent Non-controlling interests (906.131) (24.974) (931.105) 26.489 (543) 2.248 (543) Net increase in cash and cash equivalents (a)+(b)+(c) (133.065) 7.718 (92.338) Net profit/(loss) per share - basic (in €) (0,1057) 1.552 (3,9432) (670.166) 0,0153 52.422 0,3609 | 308.142 | Cash and cash equivalents at beginning of year Profit/(loss) before interest, taxes, depreciation and amortisation (EBITDA)

Profit/(loss) before interest, taxes, depreciation, amortisation and investing results (EBITDA before investing 342.472 Cash and cash equivalents of mergers
Cash and cash equivalents at end of year 168.992 9.175 259.623 82.849 83.333 1.1. - 31.12.2010 1.1. - 31.12.2009 Continuing operations operations 288.083 123.036 (792.494) (890.694) (893.059) 313.487 123.994 (810.904) (920.141) (922.761) 219.278 113.487 (1.145) (7.803) (11.350) (18.410) (29.447) (29.702) 69.939 **37.50**4 STATEMENT OF CHANGES IN EQUITY (amounts in thousands Owners of the parent Non-controlling interests (893.059) (29.702) (922.761) 48.854 (11.350) 37.50 The Group The Company
1.1. - 31.12.2010 1.1. - 31.12.2009 1.1. - 31.12.2010 1.1. - 31.12.2000 (24.007) quity balance at the beginning of the year (1.1.2010 and 1.1.2009 respectively) bals comprehensive income (net of tax) (continuing and discontinued operations) are capital increase / (decrease) equisition of subsidiaries otal comprehensive income (net of tax) (a) + (b) (893,059) (29.702) (922.761) 24.848 (11.350) 13.49 1.546.377 1.528.33 13.49 451.07 451.076 (67.324) (10.062) Owners of the parent (893.059) (29.702) (922.761) 13.497 24.848 (11.350) 0 (100) (11.338) ct of subsidiaries merge ity balance at the end of the year (31.12.2010 and 31.12.2009 respe (0,1257) 7.00 1.005.534 1.948.261 1.055.799 Dividend per share (in €)
Profit/(loss) before interest,taxes, depreciation and amortisation (EBITDA) (12.842) 18.661 rofit/(loss) before interest,taxes, depreciation, amortisation and investing results (EBITDA before investing ADDITIONAL DATA AND INFORMATION (continuation) (an ADDITIONAL DATA AND INFORMATION (amo ints in thousands f excent otherwise stated GROUP COM 1.1-31.12.2010 1.1-31.12.2009 1.1-31.12.2010 1.1-31.12.20 The companies included in the consolidated financial statements, together with their registered addresses, the consolidation method in the financial statements of the Company and their share of participation are analyzed in note 3 of the note 1 financial Recort. (28.0 2. At the end of the current fiscal year, the Company performed an impairment test, in accordance with IAS 36 "Impairment of assets", on the Goodwill paid by the company during the acquisition absidiaries. This test resulted in a total impairment loss of € 480.543 (in goodwill and other assets of the Group and the Company), as the recoverable amount of the segment (value in use) is which the adjusted carrying amount of its goodwill and not assets. The impairment amount was significantly affected by the deterioration of financial conditions such as the discount rate, the mark keyrenium and the systemic risk premium, which derive from the global financial depression and its effect on the Greek economy. Further analysis is presented in notes 16, 17 & 21 of the Annu. 4. The financial statements of the Company are not included in the consolidated financial statements of any other company.

5. There are no lligation matters which may have material impact on the financial position of the Group and the Company. The amount of provisions for any lligation matters on December 31, 2010 amounts up to € 22.193 for the Group and the Company. The Group and the Company have made no other provisions.

6. On May 6, 2010, the Greek Government enacted the 'Extraordinary Social Contribution Tax' (Law Nr 3845/2010). According to article 5, the extraordinary contribution, was applied retrespectively on ret income for the fiscal year ended December 31, 2009. The amount of such tax applicable to 2009 is 6.524 and 6.886 and these amounts are recorded as ment tax expense in the income statement of the Group and the Company respectively.

7. The number of employees at the end of current year for the Group and the Company is 1.717 and 741 respectively and for the year ended on December 31, 2009 was 2.994 and 1.364 for the Group and the Company respectively. inancial Report.

3. The Ordinary General Shareholders meeting dated May 28,2010 approved the increase of the nominal value of each share from € 0,30 to € 2.40 and at the same time the reduction of the total unber of existing shares from 1.961; 200.440 to 245.150.055 common registered shares (reverse split), with a ratio of 1 new share in replacement of 8 existing shares. Pursuant to the above, the organy's share capital amounts to € 588.360, divided into 245.150.055 shares of nominal value € 2.40 per share. On July 2.010 was the first floating date for the new shares with the new pointial value at the Althens Stock Exchange.

4. The Company has proceeded in the purchase of totally 71.578.743 treasury shares of € 91.610 value and of €1.28 per share average cost (included commissions and expenses). On December The accumulated amounts of the transactions and balances on December 31, 2010 between the Company and the associated companies as defined in IAS 24, are as follows: COMPANY GROUP 2010 after the increase of the nominal value of each share the reduction of the total number of existing shares (reverse split), the Company held 8.947.342 treasury shares. The company, duri current year and until March 29, 2011 approval date of the financial statements, did not operate any transaction regarding treasury shares. ) Income b) Expenses c) Receivables 6.678 5. The weighted average number of shares in circulation regarding all the years presented, was restated in relation to the financial statements initially reported, in order for earnings per share to 65.674 ne comparable to those of the current year. ncorne comparative to invest on the current year.

The company, in order to strengthen its capital structure, improve the financial flexibility and adjust its position in the macroeconomic environment of the country, has invited on April 4, 2011 in tracrofrany General Meeting (ECM) its Shareholders to approve, among other matters the increase in share capital of the Company in order to raise an amount of approximately € 98 mil. and therize the Board of Directors to issue convertible bond loans up to € 300 mil. on a non pre-emptive basis under the team and conditions which will be approved by EGM. The Company's anagement believes that the successful completion of the share capital increase and the potential issuing of convertible bond loans will allow the Company to implement its long term busines rategy. Besides all the afformationed, there are no events after the end of the reporting period regarding the Group and the disclosed according to the IFRSs. 12.674 2.007 e) Rewards to Managers and Members of the Board of Directors 2.007 In Receivables from Managers and Members of the Board of Directors

9 (1) Elabilities to Managers and Members of the Board of Directors

9 (1) Elabilities to Managers and Members of the Board of Directors

9 (1) Elabilities to Managers and Members of the Board of Directors

9 (1) Elabilities to Managers and Members of the Board of Directors

9 (1) Elabilities to Managers and Members of the Board of Directors

9 (2) In the consolidated in manical statements for year ended December 31, 2009 the following companies are not consolidated to the Group: GEROLYMATOS INC and HSP UNIPESSOAL LDA are fully consolidated to the Group for the first time since their acquisition and establishment date respectively. In addition GENESISI ILAC SA, which was consolidated to the Group of the first time since their acquisition and establishment date respectively. In addition GENESISI ILAC SA, which was consolidated to the Group of the first time since their acquisition and establishment date respectively. In addition GENESISI ILAC SA, which was consolidated to the Group of their within 2010 was concluded the owner's argement for joint control of GENESISI ILAC SA, in the consolidated to the Group of their within 2010 was concluded the owner's argement for joint control of GENESISI ILAC SA, in the consolidated to the Group of CENESISI ILAC SA, in the consolidated to the Group of CENESISI ILAC SA, ILAC SA, PROJUCTS LTD, THERAPETTIK SA, ELIKE IN GENESIS SA, PROJUCTS LTD, THERAPETTIK SA, ELIKE IN GENESIS SA, SHISSID HELLAS SA, ELBAUTY SA, PROJUCTS LTD, THERAPETTIK SA, ELAND DIAGNOSTICS SA, MEDIMEC SA, ALMEDIA PHARMACEUTICALS SA, KTINIATRIK PROMITHEUTIKI SA which were disposed on June 2010 - PMOMINEU INITS AWIGH were aspaces on June 2010.

10. On June 10, 2010 the Company implementing its strategy to focus on its core business segment and consequently to strengthen its competitive position in the Pharmaceutical sector, proceeded in the disposal of its non-Human Health activities, namely in Cosmicis and Liquid Detergents, Animal Health and Medical Devices sector. Particularly, the Company proceeded in the disposal of the companies GEROLYMATOS PRESTIGE SPA S BEALITY SALON SA, GEROLYMATOS ANIMAL HEALTH SA, ALAPIS MEDICAL AND DIAGNOSTICS SA, MEDIMER CSA and KTINIATRIKI - PROMITHEUTIKI SA for a contact consideration of 6144.700. The profit from the disposal of the companies mentioned above amounted in 64.979 and 61.052 for the Group and the Company respectively. These segments are presented at the current financial statements as discontinued operation according to IFRS 5 and some of the amounts of the previous financial statements were reclassified in order become companies to those of the current year. It is noted that there is no significant influence on equity and the activity of the Group due to the disposal of the companies mentioned above. Further analysis is presented in notes 20 8.29 of the Annual Financial Report.